Jason B. Fleming spends much of his time researching Pancreatic cancer, Internal medicine, Adenocarcinoma, Neoadjuvant therapy and Cancer research. Cancer covers he research in Pancreatic cancer. Jason B. Fleming combines subjects such as Gastroenterology and Oncology with his study of Internal medicine.
His Adenocarcinoma research focuses on Pathology and how it relates to Primary tumor, Pancreatic disease, Monoclonal antibody and In vivo. The Neoadjuvant therapy study combines topics in areas such as Survival rate, Pancreatectomy, Pancreaticoduodenectomy, Combined Modality Therapy and Radiology. His Cancer research research is multidisciplinary, incorporating elements of Cell growth, Cancer stem cell, Immunology, KRAS and Signal transduction.
His primary areas of study are Pancreatic cancer, Internal medicine, Cancer research, Cancer and Surgery. His research in Pancreatic cancer intersects with topics in Gemcitabine, Chemotherapy, Pathology, Radiology and Metastasis. His work in Pathology addresses issues such as Pancreas, which are connected to fields such as Neuroendocrine tumors.
His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology and Oncology. His Cancer research course of study focuses on KRAS and Oncogene. His Cancer study integrates concerns from other disciplines, such as Stage and Immunology, Lymph node.
His scientific interests lie mostly in Pancreatic cancer, Cancer research, Internal medicine, Cancer and Oncology. His Pancreatic cancer study incorporates themes from Stage, Carcinoma, Mitochondrion and Cell growth. Jason B. Fleming has researched Cancer research in several fields, including Cell, Cancer cell, Oncogene, KRAS and Tumor progression.
As part of the same scientific family, Jason B. Fleming usually focuses on Internal medicine, concentrating on Gastroenterology and intersecting with Chemoradiotherapy. His work carried out in the field of Cancer brings together such families of science as Dysplasia, Disease and Pathology. His biological study spans a wide range of topics, including Survival analysis and Chemotherapy.
The scientist’s investigation covers issues in Pancreatic cancer, Cancer research, Internal medicine, Cancer and Neoadjuvant therapy. His Pancreatic cancer research integrates issues from Signal transduction and Mitochondrion. His Cancer research research includes elements of Cancer cell, KRAS and Cell growth.
His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology and Oncology. His Cancer study combines topics in areas such as Autophagy, Mitophagy and Immunology. His Neoadjuvant therapy study which covers Survival rate that intersects with Pancreaticoduodenectomy, Adenocarcinoma, Ampulla of Vater, Stage and Metastasis.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States
James C. Yao;Manal Hassan;Alexandria T. Phan;Cecile Dagohoy.
Journal of Clinical Oncology (2008)
Glutamine supports pancreatic cancer growth through a Kras-regulated metabolic pathway
Jaekyoung Son;Costas A. Lyssiotis;Costas A. Lyssiotis;Haoqiang Ying;Xiaoxu Wang.
Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function
Andrea Viale;Piergiorgio Pettazzoni;Costas A. Lyssiotis;Haoqiang Ying.
Borderline resectable pancreatic cancer: the importance of this emerging stage of disease.
Matthew H.G. Katz;Peter W.T. Pisters;Douglas B. Evans;Charlotte C. Sun.
Journal of The American College of Surgeons (2008)
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine.
Leore T. Geller;Michal Barzily-Rokni;Tal Danino;Oliver H. Jonas;Oliver H. Jonas.
Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma
Matthew Harold Katz;Matthew Harold Katz;Huamin Wang;Jason B Fleming;Charlotte C Sun.
Annals of Surgical Oncology (2009)
KrasG12D-Induced IKK2/β/NF-κB Activation by IL-1α and p62 Feedforward Loops Is Required for Development of Pancreatic Ductal Adenocarcinoma
Jianhua Ling;Ya'an Kang;Ruiying Zhao;Qianghua Xia.
Cancer Cell (2012)
Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators
Matthew Harold Katz;Jason B Fleming;Priya R Bhosale;Gauri R Varadhachary.
Comparison of video trainer and virtual reality training systems on acquisition of laparoscopic skills.
Elizabeth Costa Hamilton;Daniel J Scott;J. B. Fleming;Robert V Rege.
Surgical Endoscopy and Other Interventional Techniques (2002)
Phase II Trial of Cetuximab, Gemcitabine, and Oxaliplatin Followed by Chemoradiation With Cetuximab for Locally Advanced (T4) Pancreatic Adenocarcinoma: Correlation of Smad4(Dpc4) Immunostaining With Pattern of Disease Progression
Christopher H. Crane;Gauri R. Varadhachary;John S. Yordy;Gregg A. Staerkel.
Journal of Clinical Oncology (2011)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: